Mitroflow and Perimount Magna 10 years outcomes a direct propensity match analysis to assess reintervention rates and long follow‐up mortality
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cardiac Surgery"
DOI: 10.1111/jocs.14250
Abstract: Biological valves are the most commonly used prostheses for aortic valve replacement (AVR) surgery in the UK. The aim of this retrospective observational study was to compare 10‐year outcomes of Perimount Magna and Mitroflow bioprosthesis… read more here.
Keywords: outcomes direct; magna years; years outcomes; perimount magna ... See more keywords
Eight‐year outcomes of aortic valve replacement with the Carpentier‐Edwards PERIMOUNT Magna Ease valve
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cardiac Surgery"
DOI: 10.1111/jocs.17140
Abstract: The Carpentier‐Edwards PERIMOUNT Magna Ease valve is a third‐generation bioprosthesis for aortic valve replacement (AVR). This is a postapproval study reporting on its 8‐year outcomes. read more here.
Keywords: magna ease; valve; perimount magna; carpentier edwards ... See more keywords
Mid-term outcomes of Sapien 3 versus Perimount Magna Ease for treatment of severe aortic stenosis
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cardiothoracic Surgery"
DOI: 10.1186/s13019-020-01203-1
Abstract: Background There is limited information on the longer-term outcome after transcatheter aortic valve replacement (TAVR) with new-generation prostheses compared to surgical aortic valve replacement (SAVR). The aim of this study was to compare the mid-term… read more here.
Keywords: savr; perimount magna; term; magna ease ... See more keywords